ArticleAdvanced healthcare materials2026
Molecular Design of Highly Efficient Heavy-Atom-Free Near-Infrared Cyanine Photosensitizers for Fluorescence Image-Guided Photodynamic Therapy of Solid Tumors.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photocontrolled nanosystem potentiates photo-chemoimmunotherapy against TNBC by integrating apoptosis/ferroptosis/ pyroptosis and STING activation.Materials today. Bio · 2026Article
- Modern Cyanine Dye-Based Photosensitizers for Medical Applications.Angewandte Chemie (International ed. in English) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Recent advancements in photodynamic therapy (PDT) have highlighted its potential as a non-invasive cancer treatment. However, to fully realize the clinical potential of PDT, the development of innovative photosensitizers is essential. In this study, efficient heavy-atom-free PSs (IR820-1-3) activated by 808 nm light irradiation were developed by incorporating electron-rich/sterically bulky groups at the meso-position of the IR820 scaffold, a novel indocyanine green derivative. Notably, experimental results and transient absorption spectroscopic studies indicated that substituent bulkiness plays a key role in promoting reactive oxygen species (ROS) generation. IR820-3 PS, with a highly twisted molecular structure, demonstrated superior ROS production via both type I and type II photochemical pathways. The self-assembled nanostructure of IR820-3 underwent partial disassembly upon interaction with albumin, resulting in enhanced fluorescence intensity and photodynamic efficiency. Interestingly, the cationic cyanine backbone facilitated the mitochondria-specific localization of IR820-3, which further contributed to IR820-3's effective PDT performance against cancer cells. Importantly, in vivo findings indicated that the IR820-3 exhibited excellent tumor-targeting ability and induced efficient tumor photoablation under 808 nm NIR irradiation. This study provides insights into the molecular design of a facile, "one-for-all" NIR photosensitizer based on a heptamethine cyanine platform, highlighting its potential for preclinical and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.